Aerium Therapeutics

What Aerium Therapeutics does

Aerium Therapeutics is a privately held biotechnology company headquartered in Boston, Massachusetts, founded in 2021. The company focuses on discovering and developing novel monoclonal antibodies (mAbs) and antiviral therapeutics directed against SARS-CoV-2 variants, positioning it within the infectious disease biologics space with a narrow, variant-adaptation thesis. Aerium operates with a very small team of 1-10 employees, consistent with an early, preclinical-stage biotech.

The company's underlying technology centers on antibody and antiviral discovery against a single viral target family, though the input does not disclose specific platform architecture, lead candidate designations, or development stage. Capital formation evidence is limited to a single disclosed funding round on 2022-03-22, backed by Omega Funds (lead) and F-Prime Capital, both reputable biotech-specialist investors; the disclosed raised amount is $0 in the input, which may reflect data capture artifact rather than an actual zero raise.

Aerium has no commercial products, no disclosed customers, no pricing model, and no revenue. Its near-term value creation will depend on advancing therapeutic candidates through preclinical milestones and ultimately toward licensing, partnership, or commercialization transactions. Operational build-out signals include the addition of a Senior Director, Medical Monitor (Kathryn Stecco), consistent with early clinical/medical affairs capability establishment.

Name

Aerium Therapeutics

Legal name

Atrium Therapeutics Inc.

Website

https://aeriumtx.com

Company type

Public

Founded year

2026

Operating status

Operating

Headcount range

1–10 employees

Short description

Aerium Therapeutics is a Boston-based, privately held biotechnology company founded in 2021 that develops monoclonal antibodies and antiviral therapeutics targeting SARS-CoV-2 variants, operating with a small early-stage team backed by institutional biotech investors.

Ownership category

akta.pro rank

Product category

Monoclonal Antibody Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Monoclonal antibody therapy
• Antiviral drug development
• SARS-CoV-2 therapeutics
• Infectious disease biologics
• Biopharmaceutical research

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Go-to-market motion1 record

Marketing channels1 record

Core offering

Aerium Therapeutics is a private biotechnology company focused on discovering and developing novel monoclonal antibodies (mAbs) and antiviral therapeutics against SARS-CoV-2 variants. The company operates as an early-stage, discovery-phase biotech headquartered in Boston, Massachusetts, with 1-10 employees and backing from healthcare-focused venture investors F-Prime Capital and Omega Funds.

Differentiator

Problem solved

Functional benefit

Products and services

• SARS-CoV-2 monoclonal antibodies (mAbs) Novel monoclonal antibody therapeutic candidates designed to neutralize SARS-CoV-2 variants, intended for use as COVID-19 treatment interventions. Currently in early-stage research and development.
• SARS-CoV-2 antiviral therapeutics Antiviral therapeutic candidates being developed against SARS-CoV-2 variants, intended to provide treatment options for COVID-19. Currently in early-stage research and development.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators2 records

Recent moves3 records

Expansion highlights2 records

Broad incumbents

• Regeneron Pharmaceuticals: Regeneron is a leading large-cap biotech that developed REGEN-COV (casirivimab/imdevimab), the first authorized COVID-19 antibody cocktail. Comparable to Aerium as a developer of monoclonal antibodies targeting SARS-CoV-2, but with vastly greater clinical, manufacturing, and commercial scale and a broad therapeutic pipeline beyond infectious disease.
• Eli Lilly: Eli Lilly developed and commercialized bebtelovimab, a SARS-CoV-2 neutralizing monoclonal antibody. Comparable to Aerium in developing variant-targeting COVID mAbs, though Lilly is a diversified large-cap pharmaceutical company with global development, manufacturing, and commercial infrastructure.
• AstraZeneca: AstraZeneca developed Evusheld (tixagevimab/cilgavimab), a long-acting antibody combination for COVID-19 pre-exposure prophylaxis. Directly comparable to Aerium in targeting SARS-CoV-2 with engineered mAbs, though AstraZeneca operates at global pharmaceutical scale across multiple therapeutic areas.

Direct peers

• Vir Biotechnology: Vir Biotechnology is a clinical-stage immunology-focused biotech that co-developed sotrovimab (with GSK) for COVID-19. Closely comparable to Aerium as a focused infectious disease antibody developer pursuing variant-resistant mAb programs, with similar clinical-stage risk profile.
• Invivyd (formerly Adagio Therapeutics): Invivyd is a clinical-stage biotech specifically focused on developing antibodies against SARS-CoV-2 variants, with lead candidate pemivibart authorized for COVID-19 pre-exposure prophylaxis. Closely comparable to Aerium in mission, modality (mAbs), target (variant-resistant SARS-CoV-2), and stage profile.

Emerging players

• Brii Biosciences: Brii Biosciences is a clinical-stage biotech that developed ambavirumab/romlusevimab, a COVID-19 antibody combination authorized in China. Comparable to Aerium as an emerging infectious disease mAb developer targeting SARS-CoV-2, with similar development-stage profile but broader geographic footprint in Asia.
• Sorrento Therapeutics: Sorrento Therapeutics is a clinical-stage biotech developing multiple therapeutic antibodies including COVID-19 candidates (e.g., STI-9167 and others). Comparable to Aerium as a smaller, multi-asset antibody developer targeting infectious disease, with similar resource constraints and clinical-stage risk profile.
• Modex Therapeutics: Modex Therapeutics is a clinical-stage antibody developer focused on infectious disease and oncology indications, including engineered antibody candidates against SARS-CoV-2 and other viral targets. Comparable to Aerium as an emerging mAb discovery and engineering platform pursuing variant-resistant antibody approaches.
• Arcturus Therapeutics: Arcturus Therapeutics developed a self-amplifying mRNA COVID-19 vaccine (Kostaive) and has broader RNA and antibody-adjacent programs. Less directly comparable to Aerium on modality (RNA vs. mAb) but adjacent as a Boston-area / San Diego small-cap infectious disease biotech with overlapping therapeutic area focus.

Regional players

• Celltrion: Celltrion developed regdanvimab (Regkirona), a COVID-19 monoclonal antibody authorized in several countries including South Korea and the EU. Comparable to Aerium as a developer of SARS-CoV-2 mAbs, though Celltrion is a larger biosimilars and biologics manufacturer primarily serving Asian and select global markets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/aeriumtx
• LinkedInlinkedin.com/company/aerium-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aerium Therapeutics